199 related articles for article (PubMed ID: 12370825)
21. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation in histologically distinct classes of breast cancer.
Bae YK; Brown A; Garrett E; Bornman D; Fackler MJ; Sukumar S; Herman JG; Gabrielson E
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
[TBL] [Abstract][Full Text] [Related]
23. Methylation of CpGs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-beta3.
Archey WB; Sweet MP; Alig GC; Arrick BA
Cancer Res; 1999 May; 59(10):2292-6. PubMed ID: 10344731
[TBL] [Abstract][Full Text] [Related]
24. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.
Ottaviano YL; Issa JP; Parl FF; Smith HS; Baylin SB; Davidson NE
Cancer Res; 1994 May; 54(10):2552-5. PubMed ID: 8168078
[TBL] [Abstract][Full Text] [Related]
25. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
26. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.
Rody A; Holtrich U; Solbach C; Kourtis K; von Minckwitz G; Engels K; Kissler S; Gätje R; Karn T; Kaufmann M
Endocr Relat Cancer; 2005 Dec; 12(4):903-16. PubMed ID: 16322330
[TBL] [Abstract][Full Text] [Related]
27. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
[TBL] [Abstract][Full Text] [Related]
28. Studies on the methylation status of CpG sequences located in promoters of selected tumour suppressor genes in breast cancer cells.
Fabianowska-Majewska K; Kordek R; Krawczyk B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1025-8. PubMed ID: 17065058
[TBL] [Abstract][Full Text] [Related]
29. [Hypermethylation of estrogen receptor-alpha gene and high homocysteine in atheromatosis patients].
Zhi Y; Huang Y; Li Z; Zhang R
Wei Sheng Yan Jiu; 2008 May; 37(3):314-7. PubMed ID: 18646531
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
31. Association between frequent CpG island methylation and HER2 amplification in human breast cancers.
Terada K; Okochi-Takada E; Akashi-Tanaka S; Miyamoto K; Taniyama K; Tsuda H; Asada K; Kaminishi M; Ushijima T
Carcinogenesis; 2009 Mar; 30(3):466-71. PubMed ID: 19168584
[TBL] [Abstract][Full Text] [Related]
32. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
33. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
Mc Cormack O; Chung WY; Fitzpatrick P; Cooke F; Flynn B; Harrison M; Fox E; Gallagher E; McGoldrick A; Dervan PA; McCann A; Kerin MJ
Breast Cancer Res Treat; 2008 Sep; 111(1):45-53. PubMed ID: 17896177
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls.
Bosviel R; Garcia S; Lavediaux G; Michard E; Dravers M; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Cancer Epidemiol; 2012 Jun; 36(3):e177-82. PubMed ID: 22402307
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
[TBL] [Abstract][Full Text] [Related]
36. [Regulation of ER(estrogen receptor) gene expression in the genesis and development of breast cancer].
Hayashi S; Yoshida T
Nihon Rinsho; 2000 Feb; 58(2):495-503. PubMed ID: 10707581
[TBL] [Abstract][Full Text] [Related]
37. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.
Rønneberg JA; Tost J; Solvang HK; Alnaes GI; Johansen FE; Brendeford EM; Yakhini Z; Gut IG; Lønning PE; Børresen-Dale AL; Gabrielsen OS; Kristensen VN
Cancer Res; 2008 Jul; 68(14):5562-71. PubMed ID: 18632608
[TBL] [Abstract][Full Text] [Related]
38. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
Bean GR; Ibarra Drendall C; Goldenberg VK; Baker JC; Troch MM; Paisie C; Wilke LG; Yee L; Marcom PK; Kimler BF; Fabian CJ; Zalles CM; Broadwater G; Scott V; Seewaldt VL
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):50-6. PubMed ID: 17220331
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic information and estrogen receptor alpha expression in breast cancer.
Giacinti L; Claudio PP; Lopez M; Giordano A
Oncologist; 2006 Jan; 11(1):1-8. PubMed ID: 16401708
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of CpG methylation in the BRCA1 promoter region.
DiNardo DN; Butcher DT; Robinson DP; Archer TK; Rodenhiser DI
Oncogene; 2001 Aug; 20(38):5331-40. PubMed ID: 11536045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
